Skip to Main Content

It was, perhaps, one of the stranger typos in recent memory: A California biotech company submitted a regulatory filing this week saying, erroneously, that it is the target of a federal investigation into painkiller prescriptions.

Galena Biopharma issued a press release Friday acknowledging the typo and saying it plans to correct it.


The San Ramon, Calif., company until recently marketed a painkiller sold as Abstral that’s prompted federal scrutiny. Two Alabama doctors have been arrested in a probe led by the local US Attorney’s Office for allegedly operating a “pill mill” and accepting kickbacks in exchange for writing prescriptions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!